



bioMérieux Acquires Accellix to Elevate Pharmaceutical Quality Control and Accelerate Advanced Therapies

Marcy-l'Étoile (France), January 22nd, 2026 – bioMérieux, a world leader in the field of *in vitro* diagnostics, announces the acquisition of Accellix, a US company specializing in rapid, automated flow cytometry solutions for cell and gene therapy quality control. With this strategic transaction, bioMérieux strengthens its Pharmaceutical Quality Control activity and invests in innovative solutions that will support the growing advanced therapy market and improve patient outcomes worldwide.

Cell and gene therapies are innovative medical treatments that use living cells or genetic modification to repair, replace, or restore function in diseased tissues, offering the potential to cure conditions once considered untreatable. From development to manufacturing, ensuring consistency, safety, and reliability is critical to building trust and unlocking the full promise of these groundbreaking treatments.

Recent analyses show that cell and gene therapies achieve clinical success rates two to three times higher than traditional treatments once they enter development, underscoring both their transformative medical impact and the need for rigorous quality frameworks to sustain patient outcomes.¹

Accellix has developed a compact flow cytometry platform that delivers results in under 30 minutes, enabling real-time quality control during cell therapy manufacturing. By simplifying complex workflows and reducing turnaround time, Accellix helps manufacturers meet stringent regulatory requirements and accelerate patient access to life-saving therapies. The company employs approximately 70 people across two locations: San José, California, United States, and Jerusalem, Israel.

Since 2020, bioMérieux has been collaborating with Accellix to serve shared key customers in the cell and gene therapy segment. It became the exclusive distributor of Accellix products locally in the Asia-Pacific region, and globally for some cell and gene therapy leaders. Thanks to this acquisition, bioMérieux will expand its portfolio in advanced therapies quality control solutions, by testing raw material and in-process quality as well as product efficacy and safety. As a partner for the pharma sector, bioMérieux will support industry demand for scalable, automated quality control tools.

“Advanced therapies, including cell and gene therapies, are redefining the future of healthcare by delivering innovative, targeted solutions for patients with complex conditions. Their promise is immense, but their success depends on uncompromising quality standards. The acquisition of Accellix positions bioMérieux at the forefront of innovation and quality control for advanced therapies, delivering solutions that meet the evolving needs of manufacturers globally. With this acquisition, we complete our offer for cell and gene therapies by building on what we already provide for sterility, mycoplasma and endotoxin testing, as well as environmental control, now adding cell purity and viability,” stated Yasha Mitrotti, Executive Vice President, Industrial Applications, bioMérieux.

“Accellix teams’ mission is to transform the status quo for quality control and blood characterization in the cell therapy and blood collection industries, helping bring life-saving treatments to patients faster than ever before. Joining bioMérieux is a powerful catalyst for growth: It will allow us to scale our technology and impact more patients’ therapy by ensuring faster, more reliable quality control processes,” added Greg Hamilton, Chief Executive Officer, Accellix.

Financial Information

bioMérieux has acquired the entire share capital of Accellix, increasing its stake from roughly 10% to 100% for a total cash out of around €35m.

Advisors

Deloitte Ltd. served as financial advisor plus Mayer Brown LLP and Herzog Fox & Neeman served as legal counsel for bioMérieux. TD Cowen served as financial advisor plus Cooley LLP and Pearl Cohen LLP as legal counsel for Accellix Inc.

¹ [New Analysis by Tufts’ NEWDIGS Shows that Durable Cell and Gene Therapies Have Substantially Higher Clinical Success Rates than Other Treatments | Center for Biomedical System Design](#)

ABOUT BIOMÉRIEUX

Pioneering Diagnostics

A world leader in the field of *in vitro* diagnostics since 1963, bioMérieux is present in 45 countries and serves more than 160 countries with the support of a large network of distributors. In 2024, revenues reached €4 billion, with over 93% of sales outside of France.

bioMérieux provides diagnostic solutions (systems, reagents, software and services) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are mainly used for diagnosing infectious diseases. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.

www.biomerieux.com.



bioMérieux is listed on the Euronext Paris stock market.

Symbol: BIM – ISIN Code: FR0013280286

Reuters: BIOX.PA/Bloomberg: BIM.FP

CONTACTS

Investors Relations

Aymeric Fichet

Tel: +33 (0)4 78 87 20 00

investor.relations@biomerieux.com

Media Relations

Corporate

Romain Duchez

Tel: +33 (0)4 78 87 20 00

media@biomerieux.com

United States

Todd Siesky

Tel: +1 919.791.5822

todd.siesky@biomerieux.com

France

Isabelle de Segonzac (Image 7)

Tel: +33 (0)1 53 70 74 85

lheilbronn@image7.fr